financetom
Business
financetom
/
Business
/
Abercrombie & Fitch Lifts Full-Year Guidance as Second-Quarter Results Top Views
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Abercrombie & Fitch Lifts Full-Year Guidance as Second-Quarter Results Top Views
Aug 27, 2025 10:47 AM

01:20 PM EDT, 08/27/2025 (MT Newswires) -- Abercrombie & Fitch ( ANF ) upgraded its fiscal 2025 outlook on Wednesday after the apparel retailer's second-quarter results exceeded Wall Street's estimates, though earnings fell year over year.

The company now expects full-year earnings between $10 and $10.50 per share, lifting the middle point versus its prior outlook of $9.50 to $10.50.

Abercrombie & Fitch ( ANF ) is now guiding full-year sales to grow 5% to 7%, faster than its previous growth outlook of 3% to 6%. Analysts polled by FactSet are looking for sales to improve to $5.22 billion from the previous year's $4.95 billion.

"We entered the second half with good momentum from the second quarter," Chief Financial Officer Robert Ball told analysts on a call, according to a FactSet transcript.

The revised guidance includes the estimated impact of tariffs in place as of Monday, including 50% for India and 30% for China, the company said. Abercrombie & Fitch ( ANF ) expects tariffs to cost about $90 million this year.

For quarter ended Aug. 2, net sales grew 7% year over year to a record $1.21 billion, narrowly beating the $1.20 billion consensus forecast. Adjusted EPS fell to $2.32 from $2.50 a year earlier, but was ahead of analysts' $2.30 estimate.

Net sales rose 8% to $974.2 million in the Americas and 12% to $37.2 million in the Asia-Pacific region. Revenue in the Europe, the Middle East and Africa market fell 1%.

By brand, Hollister net sales surged 19% to $656.7 million, while Abercrombie revenue dropped 5% to $551.9 million.

"Our strong first half and start to the third quarter gives us confidence to increase our full-year net sales forecast, building on a record 2024," Chief Executive Fran Horowitz told analysts.

For the fiscal third quarter, the company expects EPS of $2.05 to $2.25 and revenue growth of 5% to 7%. Analysts are currently projecting revenue to improve to $1.27 billion from $1.21 billion in the year-ago period.

Abercrombie & Fitch ( ANF ) shares were down 0.6% in Wednesday trading. The stock has fallen 36% so far this year.

Price: 96.55, Change: -0.19, Percent Change: -0.20

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Pfizer, BioNTech Get FDA Approval for Covid Vaccine
Pfizer, BioNTech Get FDA Approval for Covid Vaccine
Aug 27, 2025
01:00 PM EDT, 08/27/2025 (MT Newswires) -- Pfizer ( PFE ) and BioNTech (BNTX) said Wednesday the US Food and Drug Administration approved a supplemental license application for their LP.8.1-adapted monovalent COVID-19 vaccine for use in adults ages 65 and older and people ages 5 through 64 with at least one underlying condition that leaves them at high risk of...
What's Going On With Palantir Technologies Stock?
What's Going On With Palantir Technologies Stock?
Aug 27, 2025
Shares of Palantir Technologies Inc ( PLTR ) are trading lower Wednesday afternoon, continuing a recent pullback from all-time highs. Here’s what investors need to know. What To Know: The stock, a top performer this year with gains of over 100%, is now a battleground between bullish enthusiasm for its AI prowess and bearish warnings over its stretched valuation. Adding...
Rheinmetall wants to take over German shipbuilder NVL, Bild reports
Rheinmetall wants to take over German shipbuilder NVL, Bild reports
Aug 27, 2025
BERLIN, Aug 27 (Reuters) - Defence group Rheinmetall wants to take over German shipbuilder Naval Vessels Luerssen, the German daily Bild reported on Wednesday, citing industry sources. According to Bild, the Luerssen family, who own the shipbuilder, plan to divest its military shipyards in Hamburg, Wilhelmshaven and Wolgast to focus on building megayachts. Rheinmetall's supervisory board intends to consider the...
Vor Bio's Investigational Drug Scores Phase 3 Win In Autoimmune Kidney Disease Trial
Vor Bio's Investigational Drug Scores Phase 3 Win In Autoimmune Kidney Disease Trial
Aug 27, 2025
On Wednesday, Vor Bio Inc. announced that its collaborator, RemeGen Co., Ltd., achieved the primary endpoint in Stage A of a Phase 3 clinical study in China evaluating telitacicept in adults with IgA nephropathy (IgAN). IgA nephropathy, also known as Berger’s disease, is an autoimmune kidney disease where abnormal clumps of the antibody immunoglobulin A (IgA) deposit in the kidneys’...
Copyright 2023-2026 - www.financetom.com All Rights Reserved